{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-094588","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2025-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.367137+00:00","generated_at":"2026-05-18T09:00:12.692452+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"RxSight preliminary Q2 revenue $33.6M, down 4% YoY; cuts FY2025 guidance to $120-130M","bullets":["Preliminary Q2 revenue ~$33.6M, down 4% YoY and 11% sequentially; LAL volume +13% YoY, LDD sales -49% YoY.","FY2025 revenue guidance slashed to $120-130M (from $160-175M), implying 7-14% decrease from 2024.","Gross margin guidance raised to 72-74% (from 71-73%); operating expense guidance $145-155M, up 7-14% YoY.","Installed LDD base of 1,084 units (+34% YoY); management cites underperformance and plans to refocus commercial strategy.","Cash $227.5M as of June 30, 2025, down $1.8M from March 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-094588","json":"https://secwatch.observer/filing/0000950170-25-094588.json","markdown":"https://secwatch.observer/filing/0000950170-25-094588.md","text":"https://secwatch.observer/filing/0000950170-25-094588.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017025094588/0000950170-25-094588-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017025094588/rxst-20250708.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:00:12.692452+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}